Cancer cell

publication venue for

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. 2024
Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth. 2024
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. 2024
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. 2024
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. 2024
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.. 42. 2024
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. 2024
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. 2024
Shifting the landscape: The role of IDH inhibitors in glioma cell fate. 2024
Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects. 2024
Insights into how adeno-squamous transition drives KRAS inhibitor resistance.. 42. 2024
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. 2024
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. 2024
SWI/SNF regulation of germinal center fate and lymphomagenesis. 2024
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. 2024
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. 2024
A road map for the treatment of pediatric diffuse midline glioma. 2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. 2023
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers. 2023
Cooperative CAR targeting to selectively eliminate AML and minimize escape. 2023
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.. 41. 2023
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. 2023
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. 2023
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas.. 41. 2023
RECISTv1.1 progression in oncology: Shades of gray. 2023
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.. 41. 2023
Genomic mapping of metastatic organotropism in lung adenocarcinoma. 2023
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. 2023
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. 2023
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia.. 41. 2022
Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. 2022
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.. 40. 2022
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.. 40. 2022
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. 2022
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes.. 40. 2022
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence.. 40. 2022
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses.. 40. 2022
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.. 40. 2022
With one eye on the future.. 40. 2022
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells.. 39. 2021
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.. 39. 2021
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.. 39. 2021
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot.. 39. 2021
Tim-4⁺ cavity-resident macrophages impair anti-tumor CD8⁺ T cell immunity.. 39. 2021
N⁶-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation.. 39. 2021
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.. 39. 2021
Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis.. 39. 2021
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.. 39. 2021
Women in cancer research and oncology.. 39. 2021
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients.. 39. 2021
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.. 39. 2021
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19.. 38. 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.. 38. 2020
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.. 38. 2020
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution.. 38. 2020
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.. 38. 2020
Cell Lineage-Based Stratification for Glioblastoma.. 38. 2020
PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression.. 38. 2020
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.. 38. 2020
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.. 37. 2020
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.. 37. 2020
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.. 37. 2020
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.. 37. 2020
Paradigms for Precision Medicine in Epichaperome Cancer Therapy.. 36. 2019
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.. 36. 2019
Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization.. 36. 2019
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.. 36. 2019
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.. 36. 2019
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.. 36. 2019
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.. 35. 2019
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.. 35. 2019
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. 35. 2019
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.. 35. 2019
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.. 35. 2019
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.. 35. 2019
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.. 35. 2019
p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.. 35. 2018
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.. 34. 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8⁺ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.. 34. 2018
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.. 34. 2018
Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.. 34. 2018
HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.. 34. 2018
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.. 34. 2018
Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.. 34. 2018
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.. 34. 2018
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.. 33. 2018
Th9 Cells Represent a Unique Subset of CD4⁺ T Cells Endowed with the Ability to Eradicate Advanced Tumors.. 33. 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.. 33. 2018
Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.. 33. 2018
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.. 33. 2018
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.. 33. 2018
The Integrated Genomic Landscape of Thymic Epithelial Tumors.. 33. 2018
RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.. 33. 2018
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.. 33. 2018
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.. 33. 2018
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.. 33. 2017
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.. 33. 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.. 32. 2017
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.. 32. 2017
Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas.. 32. 2017
SnapShot: Chronic Lymphocytic Leukemia.. 32. 2017
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.. 32. 2017
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.. 31. 2017
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.. 31. 2017
Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells.. 31. 2016
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.. 30. 2016
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. 30. 2016
p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer.. 30. 2016
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.. 30. 2016
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.. 30. 2016
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.. 30. 2016
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.. 30. 2016
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.. 30. 2016
p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells.. 29. 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.. 29. 2016
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.. 29. 2016
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.. 29. 2016
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.. 28. 2015
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.. 28. 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.. 28. 2015
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia.. 28. 2015
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.. 27. 2015
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.. 27. 2015
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.. 27. 2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.. 27. 2015
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.. 27. 2015
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.. 27. 2015
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.. 27. 2015
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.. 27. 2015
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.. 27. 2015
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.. 27. 2015
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.. 27. 2014
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.. 26. 2014
The somatic genomic landscape of chromophobe renal cell carcinoma.. 26. 2014
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.. 26. 2014
Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.. 26. 2014
Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.. 25. 2014
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.. 25. 2014
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.. 25. 2014
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.. 25. 2014
Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance.. 25. 2014
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.. 24. 2013
A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.. 24. 2013
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.. 23. 2013
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. 23. 2013
SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism.. 23. 2013
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.. 23. 2013
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.. 23. 2013
Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration.. 23. 2013
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.. 23. 2013
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.. 22. 2012
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.. 22. 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.. 22. 2012
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.. 22. 2012
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.. 22. 2012
TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma.. 22. 2012
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.. 22. 2012
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.. 22. 2012
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia.. 22. 2012
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.. 22. 2012
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.. 21. 2012
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.. 21. 2012
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.. 21. 2012
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.. 20. 2011
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.. 20. 2011
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.. 20. 2011
Tumor entrained neutrophils inhibit seeding in the premetastatic lung.. 20. 2011
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.. 20. 2011
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.. 20. 2011
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.. 19. 2011
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.. 19. 2011
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.. 19. 2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.. 19. 2011
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.. 18. 2010
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas.. 18. 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.. 18. 2010
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.. 18. 2010
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.. 18. 2010
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.. 18. 2010
Integrative genomic profiling of human prostate cancer.. 18. 2010
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.. 17. 2010
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.. 17. 2010
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.. 17. 2010
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence.. 17. 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.. 17. 2010
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.. 17. 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.. 17. 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.. 17. 2010
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.. 17. 2010
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.. 16. 2009
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.. 16. 2009
Orai1 and STIM1 are critical for breast tumor cell migration and metastasis.. 15. 2009
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.. 14. 2008
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.. 14. 2008
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.. 14. 2008
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.. 13. 2008
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.. 13. 2008
The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis.. 13. 2008
The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.. 13. 2008
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells.. 13. 2008
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.. 12. 2007
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.. 12. 2007
A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.. 12. 2007
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.. 12. 2007
Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.. 12. 2007
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.. 12. 2007
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.. 11. 2007
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.. 11. 2007
In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma.. 11. 2007
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.. 10. 2006
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.. 10. 2006
The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.. 10. 2006
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.. 9. 2006
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.. 9. 2006
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.. 9. 2006
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.. 8. 2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.. 7. 2005
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.. 6. 2004
Molecular characterization of the tumor microenvironment in breast cancer.. 6. 2004
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.. 5. 2004
Aminopeptidase A is a functional target in angiogenic blood vessels.. 5. 2004
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN.. 5. 2004
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors.. 4. 2003
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.. 4. 2003
Second hand smoke stimulates tumor angiogenesis and growth.. 4. 2003
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.. 3. 2003
Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.. 3. 2003
Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR.. 3. 2003
Gene expression correlates of clinical prostate cancer behavior.. 1. 2002
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.. 1. 2002
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.. 26. 2014
Retraction. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.. 23. 2013
Epigenetic therapy leaps ahead with specific targeting of EZH2.. 22. 2012
IDH1 mutations disrupt blood, brain, and barriers.. 22. 2012
SnapShot: glioblastoma multiforme.. 21. 2012
A TeNaCious foundation for the metastatic niche.. 20. 2011
TORgeting oncogene addiction for cancer therapy.. 9. 2006
Mitochondrial control of antigen presentation in cancer cells. 2023
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors. 2022
Meningeal lymphatics prime tumor immunity in glioblastoma. 2021
CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck? 2020
Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens. 2018
Targeting mRNA Decapping in AML. 2018
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. 2011
A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. 2008
AKT and cancer--is it all mTOR? 2006
Fertility outcomes post immune checkpoint inhibitor exposure. 2024
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. 2024
Association of exercise with pan-cancer incidence and overall survival. 2024
Patterns of immune equilibrium and escape in indolent and progressing tumors. 2023
Clonal hematopoiesis and differential outcomes after immune checkpoint blockade. 2022
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. 2022
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. 2020
Melanoma models for the next generation of therapies. 2021
The Dual Roles of the Atypical Protein Kinase Cs in Cancer. 2019
Cytosolic DNA Sensing in Organismal Tumor Control. 2018
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. 2018
Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization. 2018
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. 2016
The journey from discoveries in fundamental immunology to cancer immunotherapy. 2015
Cancer stem cells: impact, heterogeneity, and uncertainty. 2012
Endostatin's endpoints-Deciphering the endostatin antiangiogenic pathway. 2004
Will mTOR inhibitors make it as cancer drugs? 2003
p27 as a target for cancer therapeutics. 2003
Vaccination against tumor neovascularization: Promise and reality. 2002
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? 2002
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. 2002
Cancer Molecular Analysis Project: weaving a rich cancer research tapestry. 2002
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. 2002
Functional genomics and the breast cancer problem. 2002
The hallmarks of cancer immune evasion. 2024
Immune determinants of the pre-metastatic niche. 2023
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. 2019
Focus on breast cancer. 2002

VIVO Weill Cornell Medical College

Cancer cell Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)